Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized comparison of EUS-guided radiofrequency ablation plus mFOLFIRINOX vs mFOLFIRINOX alone in pancreatic cancer
KCT0007349Phase 2Not yet recruiting
- Sponsor
- STARmed
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of FOLFIRINOX in Pancreatic neoplasia (2 arms), sponsored by STARmed. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
Pancreatic neoplasia
Beyond the preview
Go deeper on KCT0007349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007349.